Brought to you by 
Napo nets £3.15mm with private financing
10 Jan 2007
Executive Summary
Napo Pharmaceuticals, a US firm that lists on the London Stock Exchange, netted £3.15mm ($6.17mm) in a private placement of 3.5mm shares at £0.95 each (market average) to undisclosed investors. The company will use the funds to move its NP500 into Phase II trials for Type II diabetes and metabolic syndrome, and to explore a low-dose version of its Phase III crofelemer for HIV/AIDS-related diarrhea.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Private Investment in Public Equity
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Napo nets £3.15mm with private financing
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice